For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 1,266 | -883* | 1,143 | |
| General and administrative | 3,310 | -296,483* | 151,451 | |
| Total operating expenses | 4,576 | -297,366 | 152,594 | |
| Gain from operations | -4,576 | 297,366 | -152,594 | |
| Net gain and comprehensive gain | -4,576 | 297,366 | -152,594 | |
| Basic EPS | -0.02 | 1.43 | -0.76 | |
| Diluted EPS | -0.02 | 1.43 | -0.76 | |
| Basic Average Shares | 230,209,142 | 207,882,613 | 201,686,617 | |
| Diluted Average Shares | 230,209,142 | 207,882,613 | 201,686,617 | |
Semnur Pharmaceuticals, Inc. (SMNR)
Semnur Pharmaceuticals, Inc. (SMNR)